Drug intelligence / Profile preview

NN-102

Development stage: Preclinical
Lead developer: NanoNewron
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

NN-102 is a preclinical-stage nanobody (single-domain antibody) developed by NanoNewron as part of its NewroBus platform. It is designed to target Transferrin Receptor 1 (TfR1), a protein highly expressed on the brain capillary endothelial cells that form the blood–brain barrier (BBB). By binding to TfR1, NN-102 acts as a molecular shuttle, facilitating the transport of therapeutic payloads—such as other antibodies, enzymes, or small molecules—into the central nervous system (CNS) via receptor-mediated transcytosis. This platform aims to overcome the challenge of delivering large-molecule therapeutics to the brain for the treatment of various neurological disorders.

Targets

TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on NN-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NN-102.

Explore the full profile